Lineage Cell Therapeutics Inc (LTS:0HNF)
$ 1.07 0 (0%) Market Cap: 137.84 Mil Enterprise Value: 100.87 Mil PE Ratio: 0 PB Ratio: 2.55 GF Score: 60/100

Lineage Cell Therapeutics Inc To Discuss Worldwide OpRegen Collaboration Call Transcript

Dec 20, 2021 / 01:00PM GMT
Operator

Welcome to the Lineage Cell Therapeutics conference call. (Operator Instructions) An audio webcast of this call is available on the Investors section of Lineage's website at www.lineagecell.com. This call is subject to copyright and is the property of Lineage. Any recordings, reproductions or transmission of this call without the expressed written consent of Lineage are strictly prohibited. As a reminder, today's call is being recorded.

I would now like to introduce your host for today's conference call, Ioana Hone, Director of Investor Relations at Lineage. Ms. Hone, please go ahead.

Ioana C. Hone
Lineage Cell Therapeutics, Inc. - Director of IR

Thank you, Shannon. Good morning, everyone, and thank you for joining us.

Earlier this morning, Lineage Cell Therapeutics announced an exclusive worldwide collaboration with the Roche Group and Genentech for the OpRegen RPE cell therapy program. A copy of that press release can be found on the Investors section of our website.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot